Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity

Recruiting now · Phase 4

Conditions studied: Urinary Bladder, Overactive, Effect of Drug

In brief

To investigates the effects of combined pharmacotherapy with solifenacin and mirabegron versus solifenacin with vaginal estrogen cream in women with detrusor overactivity.

Key facts

Study ID

NCT06197295

Run by

Mackay Memorial Hospital

People needed

200

Starts

2022-06-16

Expected to finish

2026-12-31

Last updated by the study team

2025-05-09

Who can join

Age: 40 and older, up to 90. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Patients with detrusor overactivity which defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. Those who were refractory to monotherapy with anti-muscarinics were enrolled for prospective study.

You may not qualify if…

• Postvoid urine retention before treatment
• Women who had medical illness and contraindication for using solifenacin and mirabegron, such as narrow-angle glaucoma and hypertension
• Concerns for using estrogen include: Women with history of cerebrovascular disease; thromboembolic disorders; gallbladder disease; known or suspected breast carcinoma; estrogen-dependent neoplasm or undiagnosed abnormal genital bleeding.
• Women who were on hormone replacement therapy within 3 months were also excluded from the study

Where it is running

• Mackay Memorial Hospital — Taipei, Taiwan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.